Lundbeck CEO on most controversial drug approval in recent memory: Will bring new innovation

The FDA's approval of Biogen's aducanumab against Alzheimer's disease could lead to new and decisive breakthroughs in treatments of the disease, predicts Lundbeck CEO Deborah Dunsire.

Photo: Gregers Tycho/ERH

The most controversial drug approval by far in recent memory is met with support from pharmaceutical company Lundbeck's chief executive, Deborah Dunsire.

Unlike a range of experts, she perfectly understands the US Food and Drug Administration's approval of the drug Aduhelm (aducanumab) for treating the dreaded and deadly neurodegenerative disease Alzheimer's.

Read the whole article

Get 14 days free access.
No credit card required.

An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Lundbeck chairman demands change: "We can't live with this"

Years of work developing new treatments at Lundbeck has so far come to nothing. This has led chairman Lars Rasmusssen to demand visible results, even though CEO Deborah Dunsire has essentially had to restart development work since she joined the firm in 2018.

Eli Lilly upgrades earnings per share guidance

On Tuesday, US-based pharmaceutical firm Eli Lilly has updated elements of its 2021 financial guidance pertaining to earnings per share (non-GAAP), now expecting USD 7.95-8.05 compared to the previous USD 7.8-8.

Further reading

Related articles

Trial banner

Latest news

See all jobs